NBIX

Biotech stock Neurocrine Biosciences is hovering below its all-time high after first-quarter earnings surged more than 2,000%.

LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee. Detailed results of the vote follow: Shareholders also approved, on a non-binding advisory vote, the compensation of the Company's named executive officers, appointment of PricewaterhouseCoopers LLP to serve as the Company's auditor until the close of the Company's 2027 Annual Meeting of Shareholders, and the authorization for the board of directors to fix the auditor's remuneration. The final vote tabulation on all matters voted on at the Annual Meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company's website at www.bauschhealth.com. About Bausch HealthBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-2026-annual-meeting-of-shareholder-results-302776740.html

Xenon Pharmaceuticals XENE reported a loss of $1.17 per share in the first quarter of 2026, matching the Zacks Consensus Estimate. The company had incurred a loss of 83 cents per share in the year-ago quarter. In the reported quarter, Xenon did not generate any revenues, entirely missing the Zacks Consensus Estimate of $15 million. Due to the lack of a marketed product, the company recognizes only periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX. In the year-ago quarter, XENE recognized $7.5 million in revenues following a milestone payment from Neurocrine Biosciences in connection with the progress of NBI-921355 into a clinical-stage study. In the first quarter, research and development (R&D) expenses increased 45% year over year to $88.5 million. The uptick was primarily due to increased expenses related to Xenon’s ongoing azetukalner late-stage studies in epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Costs incurred in supporting the early-stage studies of XEN1701 and XEN1120, as well as increased personnel-related costs, also contributed to higher R&D expenses. General and administrative expenses totaled $23.8 million in the reported quarter, up 25% year over year due to higher personnel expenses from a larger workforce and increased professional and consulting fees. Xenon had cash, cash equivalents and marketable securities worth $1,339.6 million as of March 31, 2026, compared to $586.0 million as of Dec. 31, 2025. During the reported quarter, the company raised net proceeds of $130 million through its ATM program and an additional $707.6 million via a public offering. Based on its current operating plans, Xenon expects its existing cash position to support operations into 2029. Year to date, XENE shares have gained 24.9% against the industry’s 0.2% decline. Image Source: Zacks Investment Research In March 2026, Xenon announced positive top-line data from the phase III X-TOLE2 study, which evaluated its lead pipeline candidate, azetukalner, for treating focal onset seizures (FOS). The X-TOLE2 study evaluated the efficacy, safety and tolerability of 15 mg and 25 mg doses of azetukalner, given with food as an add-on treatment in patients with FOS. The study met its primary endpoint, showing a median percent change (MPC) in monthly FOS frequency from baseline to week 12 f...

As you might know, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) just kicked off its latest quarterly results with some very strong numbers. It was overall a positive result, with revenues beating expectations by 6.4% to hit US$815m. Neurocrine Biosciences also reported a statutory profit of US$1.91, which was an impressive 61% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Taking into account the latest results, the most recent consensus for Neurocrine Biosciences from 18 analysts is for revenues of US$3.76b in 2026. If met, it would imply a huge 21% increase on its revenue over the past 12 months. Statutory earnings per share are forecast to tumble 25% to US$5.01 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.72b and earnings per share (EPS) of US$4.59 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates. View our latest analysis for Neurocrine Biosciences The consensus price target was unchanged at US$191, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Neurocrine Biosciences analyst has a price target of US$251 per share, while the most pessimistic values it at US$144. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Neurocrine Biosciences shareholders. Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Neurocrine Biosciences' growth to accelerate, with the forecast 29% a...

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026. "Neurocrine's strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas," said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We delivered $811 million in net product sales, representing 44% year-over-year growth, driven by continued strong demand for INGREZZA and CRENESSITY® (crinecerfont). Our recently announced agreement to acquire Soleno Therapeutics further underscores our commitment to address conditions with significant unmet need and accelerate revenue growth. With multiple first-in-class commercial medicines and the deepest pipeline in our history, Neurocrine is well-positioned to deliver transformative therapies for patients and drive sustained growth." Net Product Sales Highlights Total first-quarter 2026 net product sales were $811.0 million, representing 44% growth year-over-year. INGREZZA first-quarter 2026 net product sales were $656.9 million, representing 20% growth year-over-year. Results reflected double-digit prescription volume growth in TRx and record NRx driven by strong patient demand, partially offset by a lower net price compared to the first quarter of 2025. CRENESSITY first-quarter 2026 net product sales were $153.3 million, driven by strong patient demand with approximately 80% reimbursement for dispensed prescriptions in the first quarter 2026. Total revenues for the first quarter of 2026 were $814.5 million, compared with $572.6 million in the prior-year period, a 42% increase. Recent Clinical and Corporate Developments Entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total transaction equi...

Neurocrine Biosciences (NBIX) reported $814.5 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 42.3%. EPS of $1.94 for the same period compares to $0.08 a year ago. The reported revenue represents a surprise of +9.8% over the Zacks Consensus Estimate of $741.78 million. With the consensus EPS estimate being $1.68, the EPS surprise was +15.31%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product sales, net- INGREZZA: $656.9 million compared to the $595.65 million average estimate based on eight analysts. The reported number represents a change of +20.5% year over year. Revenues- Product sales, net: $811 million versus the eight-analyst average estimate of $720.97 million. The reported number represents a year-over-year change of +43.9%. Revenues- Product sales, net- CRENESSITY: $153.3 million compared to the $121.77 million average estimate based on eight analysts. Revenues- Collaboration revenue: $3.5 million versus the seven-analyst average estimate of $7.72 million. The reported number represents a year-over-year change of -60.7%. Revenues- Product sales, net- Other: $4.3 million versus $4.1 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change. View all Key Company Metrics for Neurocrine here>>> Shares of Neurocrine have returned +1.2% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report...

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Tuesday reported first-quarter net income of $197.9 million. On a per-share basis, the San Diego-based company said it had net income of $1.91. Earnings, adjusted for one-time gains and costs, came to $1.94 per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.68 per share. The biopharmaceutical company posted revenue of $814.5 million in the period, which also topped Street forecasts. Nine analysts surveyed by Zacks expected $741.8 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NBIX at https://www.zacks.com/ap/NBIX

Neurocrine Biosciences (NBIX) reported Q1 adjusted earnings late Tuesday of $1.94 per diluted share,

Record quarterly revenue: Neurocrine reported Q1 net product sales above $800 million, driven primarily by INGREZZA (Q1 sales $657M), and reaffirmed full-year INGREZZA guidance of $2.7–$2.8 billion. CRENESSITY momentum and data: CRENESSITY posted $153 million in Q1 with strong persistency, favorable reimbursement and ~1,200 prescribers, and two‑year Phase III data showed durable glucocorticoid dose reductions with no new safety signals. Pipeline growth and Soleno timeline: Neurocrine plans multiple Phase I/II starts in 2026 and expects 2027 readouts for several programs (osavampator, direclidine, NBIP‑2118), while the acquisition of Soleno Therapeutics (adding VYKAT XR) remains on track to close in Q2. Interested in Neurocrine Biosciences, Inc.? Here are five stocks we like better. 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) reported first-quarter 2026 results highlighted by record quarterly revenue and continued growth from its two commercial products, INGREZZA and CRENESSITY, while company executives also discussed pipeline progress and the expected closing timeline for its pending acquisition of Soleno Therapeutics. Chief Executive Officer Kyle Gano said the company’s first-quarter performance reflected “meaningful progress” toward its goal of expanding and diversifying its revenue base. For the first time in company history, quarterly net product sales exceeded $800 million, representing 44% year-over-year growth, which Gano said was “primarily driven by INGREZZA.” → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals Chief Financial Officer Matthew Abernethy said Neurocrine delivered more than $800 million in total revenue, with “over 40% year-over-year growth.” INGREZZA first-quarter sales were $657 million, up 20% year-over-year, driven by “double-digit volume growth and record new patient additions,” he said. Abernethy added that when adjusting for one less order week in the prior-year quarter, growth was approximately 11%. Neurocrine reaffirmed its full-year 2026 INGREZZA guidance of $2.7 billion to $2.8 billion. Abernethy said the company plans to revisit guidance after the first half of the year, consistent with its historical approach. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches Is Mid-Cap...

Achieved record quarterly net product sales exceeding $800 million, a 44% year-over-year increase, driven by sustained double-digit growth in the INGREZZA franchise and rapid CRENESSITY adoption. INGREZZA performance was bolstered by record new patient additions and improved formulary access, despite typical first-quarter seasonal payer disruptions and one fewer order week compared to the prior year. CRENESSITY is annualizing at over $600 million in its fifth launch quarter, with management attributing success to high persistency rates and broad adoption across pediatric and adult endocrinology segments. The company is executing a significant commercial expansion, with the full impact of the enlarged sales force expected to materialize starting in the second quarter of 2026. Strategic portfolio diversification is being advanced through the pending acquisition of Soleno Therapeutics, aimed at integrating VYKAT XR to serve the Prader-Willi Syndrome market. Management highlighted a shift toward a tiered endocrine strategy, positioning CRENESSITY as a foundational first-line therapy while developing pipeline assets like NBIP-1435 for alternative administration and second-line use. Reaffirmed full-year 2026 INGREZZA guidance of $2.7 billion to $2.8 billion, with plans to revisit these figures following the completion of the first half of the year. Anticipates 2027 to be a pivotal year for clinical data, with major readouts expected for osavampator in depression, direclidine in schizophrenia, and NBIP-2118 in obesity. The acquisition of Soleno Therapeutics and VYKAT XR is on track to close in Q2 2026, with detailed financial guidance for the transaction expected during the Q2 earnings call. Pipeline expansion continues with plans to initiate 6 new Phase I and 4 new Phase II programs in 2026. Future growth assumptions for INGREZZA include tailwinds from rising antipsychotic utilization and increased screening for tardive dyskinesia in long-term care settings. Divested the Diurnal business to an organization better suited for the European commercial landscape, resulting in a GAAP gain during the quarter. Reported $44 million in milestone expenses related to In-Process R&D (IP&D) within non-GAAP results, reflecting ongoing pipeline investment. Noted slight gross-to-net pressure for CRENESSITY in Q1 due to typical commercial co-pay resets at the start of the calendar...

Image source: The Motley Fool. Tuesday, May 5, 2026 at 4:30 p.m. ET Chief Executive Officer — Kyle Gano Chief Financial Officer — Matthew C. Abernethy Chief Commercial Officer — Eric S. Benevich Chief Medical Officer — Sanjay Keswani Need a quote from a Motley Fool analyst? Email [email protected] Kyle Gano: Thanks, Todd. Good afternoon, everyone. Over the past several years, we have articulated a clear vision to become a leading biopharmaceutical company driven by growing and diversifying our revenue base while advancing and expanding our pipeline. Our first quarter performance reflects meaningful progress along that path. For the first time in Neurocrine Biosciences, Inc.’s history, quarterly net product sales exceeded $800 million, representing 44% year-over-year growth. These outstanding results were primarily driven by INGREZZA, now in its ninth year since launch and continuing to grow at a double-digit rate. With INGREZZA guidance reaffirmed at $2.7 to $2.8 billion, Cranesini now annualizing at over $600 million per year, and the pending addition of iCAT XR to our commercial portfolio, we are well positioned to deliver record net product sales in 2026. Regarding VICAT XR and the pending acquisition of Soleno Therapeutics, we will be limited in our ability to address questions today given the ongoing tender offer. The acquisition remains on track to close in the second quarter. That said, we have been impressed by the Solano team's accomplishments in delivering strong clinical results in a complex disease, enabling broad utilization with a simple label, and overseeing a strong launch of iCAD XR. We look forward to formally welcoming them to the Neurocrine Biosciences, Inc. team shortly. Together, we will remain focused on ensuring a seamless integration with a singular goal of serving patients with Prader-Willi syndrome in the United States. Beyond strengthening our commercial portfolio, we continue to invest in our R&D engine across neurology, psychiatry, endocrinology, and immunology. Our pipeline progress is evident by our plan for six new phase 1 and four new phase 2 programs this year alone. In 2027, we will report key data readouts for rosuvampodoro in major depressive disorder, dereclidine in schizophrenia, and MBIP 2118 in obesity, just to name a few. When you combine the durability and remaining growth opportunity for our commercial assets, our innov...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +15.31%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $2.25 per share when it actually produced earnings of $1.88, delivering a surprise of -16.44%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Neurocrine, which belongs to the Zacks Medical - Drugs industry, posted revenues of $814.5 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 9.80%. This compares to year-ago revenues of $572.6 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Neurocrine shares have lost about 5.5% since the beginning of the year versus the S&P 500's gain of 5.2%. While Neurocrine has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Neurocrine was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank...